Oregon Drug Use Review / Pharmacy & Therapeutics Committee
Thursday, February 04, 2021 1:00 - 5:00 PM
Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Mark Helm, MD, MBA, FAAP; Russell Huffman, DNP, PMHNP; Cathy Zehrung RPh; Patrick DeMartino, MD; Cat Livingston, MD, MPH; Stacy Ramirez, PharmD; Tim Langford, PharmD, BCPS, USPHS; Caryn Mickelson, PharmD; Robin Moody, MPH; William Origer, MD, FAAFP.

Staff Present: Jennifer Bowen, Admin; Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Dean Haxby, PharmD; Richard Holsapple, RPh; Kathy Sentena, PharmD; Sarah Servid, PharmD; Dee Weston, JD; Amanda Parrish, LCSW; Brandon Wells

Audience: Sami Nasrawi, Alnylam Pharmaceuticals*; Andrea Wilcuts, Takeda Pharmaceuticals; Brandi Ferger, Advanced Health; Camille Kerr, Regeneron; Chi Kohlhoff, Viela Bio; Christina Hartman; Crystal Cooper-Siegel, Alexion; Debby Ham, Aimmune Therapeutics; Erika Finanger, MD, OHSU; Eva Solis, Jean Ritter, Zealand Pharma; Jenny Todenhagen; Jerey Stand, Alexion; Jim Cromwell; Jim Graves, BMS; Katie Scheelar, Moda Health; Kelly Maynard, Little Hercules Foundation*; Mark Kantor, AllCare Health; Matt Worth, OHSU; Timothy McFerron, Alkermes; Meganne Leach, PNP, OHSU; Michael Foster, BMS; Mike Nicholson; Norm Navarro, Providence; Paul Thompson, Alkermes; Rachel Hartman, IHN; Rebekah Bartholomew, OSU; Richard Dabner, Alnylam Pharmaceuticals; Rick Frees, Vertex; Suzanne Morgan, Tiffany Jones, PacifiSource; Tracy Copeland, Sarepta Therapeutics*; Wendy Bibeau, BMS. Stephanie Yamamoto, Janssen Scientific Affairs*

(*) Provided verbal testimony

Written testimony: Posted to OSU Website
I. CALL TO ORDER

A. The meeting was called to order at approximately 1:06 pm. Introductions were made by Committee members and staff
B. Conflict of Interest Declaration - No new conflicts of interest were declared
C. The Committee elected Stacy Ramirez as the chair and Bill Origer as the vice chair
D. Approval of December 2020 minutes presented by Mr. Citron
   ACTION: Motion to approve, 2nd, all returning members in favor, new members abstained
E. Department and legislative update provided by Dee Weston

II. CONSENT AGENDA TOPICS

A. P&T Methods and Operating Procedures
B. Orphan Drug PA update
C. Oncology Policy Update
D. Anticoagulant Literature Scan
   Recommendations:
   - No PDL changes recommended based on the clinical evidence
   - Evaluate costs in executive session
   Public Comment: Sami Nasrawi, Alnylam Pharmaceuticals
   ACTION: Motion to approve, 2nd, all in favor

III. DUR ACTIVITIES

A. Quarterly Utilization Report: Roger Citron, RPh
B. ProDUR Report: Rich Holsapple, RPh
C. RetroDUR Report: Dave Engen, PharmD
D. Oregon State Drug Review: Kathy Sentena, PharmD
   - New Disease-Modifying Anti-Rheumatic Drugs for management of Rheumatoid Arthritis
   - Cardiovascular Outcomes Associated with Newer Therapy Classes for Type 2 Diabetes Mellitus

IV. PREFERRED DRUG LIST NEW BUSINESS

A. Duchenne Muscular Dystrophy (DMD) Class Update and DERP Report with New Drug Evaluation (NDE): Sarah Servid, PharmD
Recommendations:
- Update prior authorization (PA) criteria for DMD to include viltolarsen to ensure medically appropriate use
- Evaluate costs in executive session

Public Comment: Tracy Copeland, Medial Affairs, Sarepta Therapeutics; Kelly Maynard, Little Hercules Foundation
ACTION: Motion to approve, 2nd, all in favor

B. Acne Class Update with NDE: Sara Fletcher, PharmD
Recommendations:
- Designate clascoterone as non-preferred on the PDL
- Evaluate costs in executive session
ACTION: Motion to approve, 2nd, all in favor

C. Treatments for Peanut Allergy: Sara Fletcher, PharmD
Recommendations:
- Create “Peanut Desensitization” PDL class within Immunology
- Designate Palforzia as non-preferred based on clinical Information
- Implement PA criteria to ensure appropriate use of Palforzia for funded conditions
Public Comment: Debbie Ham, Medical Affairs, Aimmune Therapeutics
ACTION: The Committee recommended amending the proposed criteria to specify Epi use/ER visit/hospitalization associated with peanut exposure; to amend the renewal criteria to specify absence or reduction in ER visits/hospitalizations; and to rename the class “Immunotherapy Desensitization” so not specific to only peanuts
Motion to approve, 2nd, all in favor

D. Smoking Cessation Literature Scan: Dave Engen, PharmD
Recommendation:
- No PDL changes recommended based on the clinical evidence
- Update PA criteria to allow varenicline therapy for two 12-week treatment regimens within 1 year for patients 17 years of age and older
- Evaluate costs in executive session
ACTION: The Committee recommended removing the PA requirement from preferred products
Motion to approve, 2nd, all in favor

E. Antidepressant Class Update: Sarah Servid, PharmD
Recommendation:
- No PDL changes recommended based on the clinical evidence
- Update esketamine safety edit to accommodate new indication
- Evaluate costs in executive session
Public Comment: Stephanie Yamamoto, Janssen Scientific Affairs
ACTION: The Committee recommended amending the renewal criteria to include an assessment of adherence to oral antidepressant therapy
Motion to approve, 2nd, all in favor

F. **Non-Steroidal Anti-Inflammatory Drug (NSAID) Class Update**
   **Recommendation:**
   - No PDL changes recommended based on the clinical evidence
   - Evaluate costs in executive session
   **ACTION: Motion to approve, 2nd, all in favor**

---

**V. EXECUTIVE SESSION**

**Members Present:** Mark Helm, MD, MBA, FAAP; Russell Huffman, DNP, PMHNP; Cathy Zehrung RPh; Patrick DeMartino, MD; Cat Livingston, MD, MPH; Stacy Ramirez, PharmD; Tim Langford, PharmD, BCPS, CDE, USPHS; Caryn Mickelson, PharmD; Robin Moody, MPH; William Origer, MD, FAAFP

**Staff Present:** Jennifer Bowen, Admin; Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Richard Holsapple, RPh; Kathy Sentena, PharmD; Sarah Servid, PharmD; Dee Weston, JD; Brandon Wells

**VIII. RECONVENE for PUBLIC RECOMMENDATIONS**

A. **Anticoagulant Literature Scan:**
   **Recommendation:** Make dalteparin syringes non-preferred on the PDL
   **ACTION: Motion to approve, 2nd, all in favor**

B. **Duchenne Muscular Dystrophy Class Update:**
   **Recommendation:** No changes to the PDL are recommended
   **ACTION: Motion to approve, 2nd, all in favor**

C. **Acne Class update:**
   **Recommendation:** Make benzoyl peroxide (BPO) lotion and erythromycin/BPO gel preferred; and make BPO towelette non-preferred on the PDL
   **ACTION: Motion to approve, 2nd, all in favor**

D. **Smoking Cessation Literature Scan:**
   **Recommendation:** No changes to the PDL are recommended
   **ACTION: Motion to approve, 2nd, all in favor**
E. **Antidepressants Class Update:**
   **Recommendation:** Make duloxetine DR capsules, bupropion HCL XL 24H tablets (Wellbutrin XL & associated generics), and desvenlafaxine succinate ER 24H tablets preferred; and make amoxapine tablets voluntary non-preferred. Explore RetroDUR opportunities for dose consolidation with vortioxetine and change forms to switch utilization from desvenlafaxine 24H ER tabs to desvenlafaxine succinate 24H ER tabs
   **ACTION:** Motion to approve, 2nd, all in favor

F. **NSAID Class Update:**
   **Recommendation:** Make celecoxib (brand and generic) preferred. Make Qmiiz ODT, flurbiprofen and ketorolac tablets non-preferred on the PDL
   **ACTION:** Motion to approve, 2nd, all in favor

**IX. ADJOURN**